OTCMKTS:ALPMY Astellas Pharma 10/29/2026 Earnings Report $14.21 -0.11 (-0.77%) As of 10/5/2026 03:53 PM Eastern ProfileEarnings HistoryForecast Astellas Pharma EPS ResultsActual EPSN/AConsensus EPS $0.39Beat/MissN/AOne Year Ago EPSN/AAstellas Pharma Revenue ResultsActual RevenueN/AExpected Revenue$3.70 billionBeat/MissN/AYoY Revenue GrowthN/AAstellas Pharma Announcement DetailsQuarterDate10/29/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Astellas Pharma Earnings HeadlinesAstellas Pharma (OTCMKTS:ALPMY) Shares Gap Up - Here's WhyOctober 3 at 5:41 AM | americanbankingnews.comAstellas Pharma Inc. (OTCMKTS:ALPMY) Shares Shorted: Short Interest Down 64.5% in SeptemberSeptember 27, 2026 | americanbankingnews.comThe AI Stock to Keep an Eye on Before Election Day (See Why)In 2019, Charles Mizrahi named Marvell Technology his top AI pick. It's since climbed 1300 percent. Now he's pointing to a different company tech giants rely on to power their AI networks, one that's not yet a household name despite receiving 10 billion dollars a year in funding. The global AI market is projected to grow more than 1800 percent, reaching 5.2 trillion dollars by 2035. | Prosperity Research (Ad)Mizuho Securities Sticks to Their Hold Rating for Astellas Pharma (ALPMF)September 15, 2026 | theglobeandmail.comAstellas Pharma (ALPMF) Receives a Hold from Morgan StanleyAugust 20, 2026 | theglobeandmail.comAstellas Halts Early KRAS G12D Cancer Trial: What It Means for ALPMF InvestorsJuly 16, 2026 | tipranks.comSee More Astellas Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Astellas Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Astellas Pharma and other key companies, straight to your email. Email Address About Astellas PharmaAstellas Pharma (OTCMKTS:ALPMY) is a Japan-based pharmaceutical company that researches, develops, manufactures and commercializes prescription medicines for patients worldwide. Its portfolio focuses on areas of significant unmet medical need, including oncology, immunology, urology, ophthalmology, neuroscience and medical conditions related to genetic regulation. The company’s products include XTANDI (enzalutamide) for certain prostate cancers, XOSPATA (gilteritinib) for acute myeloid leukemia, PADCEV (enfortumab vedotin-ejfv) for certain urothelial cancers, and PROGRAF (tacrolimus), an immunosuppressant used primarily to help prevent organ rejection following transplantation. Astellas also develops medicines and investigational therapies through internal research and collaborations with biotechnology and pharmaceutical companies. Astellas was established in 2005 through the merger of Yamanouchi Pharmaceutical Co. and Fujisawa Pharmaceutical Co., two Japanese companies with histories dating back several decades. Headquartered in Tokyo, the company serves markets across North America, Europe, Asia and other regions through a global research, development and commercial organization. Naoki Okamura serves as Astellas Pharma’s president and chief executive officer.View Astellas Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles NVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can RunMarketBeat Week in Review – 09/28 - 10/02Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?Time to Nibble on MCD Stock After it Enters Oversold Territory?Liberty Energy’s AI Power Push Has Wall Street DividedMcCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last Longer Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
